Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • Schlich China
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
  • Patent Specialities
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
New Referral to the Enlarged Board of Appeal on the Use of Post-Published Data to Support Inventive Step Confirmed

New Referral to the Enlarged Board of Appeal on the Use of Post-Published Data to Support Inventive Step Confirmed

by Eddie Bishop | Feb 8, 2022 | EPO

Background In our previous article, we discussed the expected referral to the Enlarged Board of Appeal in case T 116/18, wherein the Board of Appeal decided greater clarity was required concerning the use of post-published data when considering inventive step. The...
A New Standard for Submitting Protein and Nucleic Acid Sequences – “ST.26”

A New Standard for Submitting Protein and Nucleic Acid Sequences – “ST.26”

by Schlich | May 1, 2021 | US & International

Up until now, there has been an international system for disclosing nucleic acid and proteins sequences in a format that can be used by patent offices for searching and examination of patent applications. This system is administered by the World Intellectual Property...
Updated Guidelines for Chinese Patent Examination

Updated Guidelines for Chinese Patent Examination

by Schlich | Feb 1, 2021 | US & International

Key Revisions to the Chinese Guidelines for Patent Examination Supplementary Data Historically, in China, the rules on submitting supplementary data in favour of sufficiency and/or inventive step have been very strict throughout patent prosecution. This was bad news...
T844/18 Confirms Legal Certainty in the EPO’s Consistent Interpretation of the Priority Provisions in Art. 87(1) EPC

T844/18 Confirms Legal Certainty in the EPO’s Consistent Interpretation of the Priority Provisions in Art. 87(1) EPC

by Schlich | Nov 1, 2020 | EPO

Overview of decision On 6 November 2020, the EPO Technical Board of Appeal (TBA) formally (and finally) handed down its written decision in T844/18 relating to priority and confirmed revocation of the Broad Institute Inc.’s CRISPR/Cas9 patent EP2771468[3]. This...
Broadest Reasonable Interpretation of a Claim in the US Should be in Light of the Specification

Broadest Reasonable Interpretation of a Claim in the US Should be in Light of the Specification

by Schlich | Nov 1, 2020 | US & International

Snyders’ Heart Valve Patent Snyders’ patent was to an artificial heart valve that crucially can be inserted into place without removing the native damaged valve. This is explicitly stated in the description with further details of how the artificial valve...
« Older Entries

Recent Posts

  • A New European Court to Administer an EU Patent
  • Unitary patents are coming – are they right for you?
  • UKIPO cannot raise ex officio bad faith objections
  • UK Court Has Jurisdiction to Grant Interim Injunction Before Formal Granted Patent
  • Latest developments in the EPO’s description amendment saga

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UK IPO Proceedings
    • Trade Marks
    • Designs

    About

    • Our Firm
    • Careers
    • Our People

    Contact

    • Contact
    • Inventors Zone
    © 2021 Schlich, All rights reserved | Privacy Policy | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.